

The estimated number of recordkeepers (i.e., persons that separate mammalian and nonmammalian materials), is derived from inspections of firms handling animal protein intended for use in animal feed. The estimate of the time required for this recordkeeping requirement is based on agency communication with industry.

Dated: January 9, 2004.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. 04-1062 Filed 1-15-04; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Notice of Approval of New Animal Drug Application; Ceftiofur

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is providing notice that it has approved a supplemental new animal drug application (NADA) filed by Pharmacia & Upjohn Co. The supplemental NADA provided revised susceptibility information for food-animal pathogens listed in the clinical microbiology section of labeling for ceftiofur hydrochloride injectable suspension.

**FOR FURTHER INFORMATION CONTACT:** Joan C. Gotthardt, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7571, e-mail [jgotthar@cvm.fda.gov](mailto:jgotthar@cvm.fda.gov).

**SUPPLEMENTARY INFORMATION:** Pharmacia & Upjohn Co., 7000 Portage Rd., Kalamazoo, MI 49001-0199, filed a supplement to NADA 140-890 which provides for the veterinary prescription use of EXCENEL (ceftiofur hydrochloride) RTU Sterile Suspension. The supplemental NADA provided updated susceptibility data for food-animal pathogens listed in the clinical microbiology section of labeling. In accordance with section 512(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(i)) and 21 CFR 514.105(a) and 514.106(a), FDA is providing notice that this supplemental NADA is approved as of December 12, 2003. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to

support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: December 31, 2003.

**Steven D. Vaughn,**

*Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*

[FR Doc. 04-941 Filed 1-15-04; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Advisory Committee on Interdisciplinary, Community-Based Linkages; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), notice is hereby given of the following meeting.

**Name:** Advisory Committee on Interdisciplinary, Community-Based Linkages.

**Dates and Times:** February 9, 2004, 8:30 a.m.-5:30 p.m., February 10, 2004, 8:30 a.m.-5:30 p.m., February 11, 2004, 8:30 a.m.-4 p.m.

**Place:** The Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

**Status:** The meeting will be open to the public.

**Agenda:** Agenda items will include, but not be limited to: Welcome; plenary session on healthcare disparities as it relates to the grant programs under the purview of the Committee with presentations by speakers representing the Department of Health and Human Services (DHHS), constituent groups, field experts and committee members. The following topics will be addressed at the meeting: What is the relationship between health disparities and underserved/unserved populations; what is the impact of health disparities on Title VII programs, what are Title VII programs doing in terms of legislative requirements, and what are the best practices to address health disparities employed by Title VII programs; and what are complementary programs doing to address health disparities, what are their best practices, and how can we collaborate with these partners to build on existing infrastructures and to maximize resources to address health disparities.

Proposed agenda items are subject to change as priorities dictate.

**Public Comments:** Public comment will be permitted at the end of the Committee meeting on February 9, 2004 and before lunch on February 10, 2004. Oral presentations will be limited to 5 minutes per public speaker. Persons interested in providing an oral presentation should submit a written request, with a copy of their presentation to: Jennifer Donovan, Deputy Executive Secretary, Division of State, Community and Public Health, Bureau of Health Professions, Health Resources and Services Administration, Room 9-105, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443-8044.

Requests should contain the name, address, telephone number, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative. The Division of State, Community and Public Health will notify each presenter by mail or telephone of their assigned presentation time.

Persons who do not file a request in advance for a presentation, but wish to make an oral statement may register to do so at the Double Tree Hotel, Rockville, MD, on February 9, 2004. These persons will be allocated time as the Committee meeting agenda permits.

**For Further Information Contact:** Anyone requiring information regarding the Committee should contact Jennifer Donovan, Division of State, Community and Public Health, Bureau of Health Professions, Health Resources and Services Administration, Room 9-105, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443-8044.

Dated: January 12, 2004.

**Tina M. Cheatham,**

*Acting Director, Division of Policy Review and Coordination.*

[FR Doc. 04-1063 Filed 1-15-04; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.